Cyclin D as a therapeutic target in cancer
The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Failure to modify cyclin D1 on T286 leads to aberrant nuclear accumulation of the protein, premature S phase entry, and enhanced cellular proliferation that drives tumorigenesis (17).”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [17]
In the citing paper
“Possibly, CCND1 amplification and CDKN2A loss may contribute to determining response to letrozole alone”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [68]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“The deregulation of cyclin expression or CDK activation can directly lead to some of the hallmarks of cance”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“A second well-described non-catalytic role of cyclin D is the sequestration of p21 and p27 by cyclin D–CDK4/CDK6, leading to the indirect activation of CDK2 (REF”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“It may also be possible to identify low-molecular-mass inhibitors of cyclin–CDK substrate interactions using high-throughput screens that are similar to those used for the discovery and preclinical testing of inhibitors of MDM2–p53 binding (nutlins”
MethodThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“by causing proliferation that is independent of normal extracellular cues, or by over-riding checkpoints that ensure genomic integrity and stabilit”
BackgroundFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387 · cited 1×
“Given the increasingly routine clinical use of specific kinase inhibitor”
BackgroundmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · cited 1×
“In Phase II clinical trials mTOR inhibitors were particularly effective in MCL, which is characterized by almost universal overexpression of cyclin D1, although this may not be accompanied by a reduction in cyclin D1 expression (reviewed in REF”
BackgroundBiological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Self-citation
Cited by
Items 501–600 of 1,000
Role of Piperine in Chemoresistance
Kumar, S., Bhandari, C., Sharma, P., & Agnihotri, N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812373-7.00013-9 · Cited by 35
Sato, S., Nagahashi, M., Koike, T., Ichikawa, H., Shimada, Y., Watanabe, S., Kikuchi, T., Takada, K., Nakanishi, R., Oki, E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18560-y · Cited by 30
The Chemopreventive Activity of Indonesia Medicinal Plants Targeting on Hallmarks of Cancer
Meiyanto, E., & Larasati, Y. A. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.025 · Cited by 32
Rivello, F., Matuła, K., Piruska, A., Smits, M., Mehra, N., & Huck, W. T. S. (2020) · Science Advances · doi:10.1126/sciadv.aaz3849 · Cited by 31
González‐Ruiz, L., González‐Moles, M. Á., González‐Ruiz, I., Ruiz‐Ávila, I., & Ramos‐García, P. (2021) · Cancers · doi:10.3390/cancers13061314 · Cited by 33
“The frequent CCND1/cyclin D1 upregulation in melanomas has stimulated the research of cyclin D1 inhibitors as a therapeutic tool [59].”
BackgroundAkbari, E., Mousazadeh, H., Hanifehpour, Y., Mostafavi, E., Gorabi, A. M., Nejati‐Koshki, K., Keyhanvar, P., Pazoki–Toroudi, H., Mohammadhosseini, M., & Akbarzadeh, A. (2021) · Journal of Cluster Science · doi:10.1007/s10876-021-02101-9 · Cited by 30
Cell cycle-regulatory cyclins and their deregulation in oral cancer
Mishra, R. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.01.008 · Cited by 30
“[136]).”
Jirawatnotai, S., Sharma, S., Michowski, W., Suktitipat, B., Geng, Y., Quackenbush, J. F., Elias, J. E., Gygi, S. P., Wang, Y. E., & Siciński, P. (2014) · Cell Cycle · doi:10.4161/15384101.2014.946850 · Cited by 30
Ito, K., Maruyama, Z., Sakai, A., Izumi, S., Moriishi, T., Yoshida, C. A., Miyazaki, T., Komori, H., Takada, K., Kawaguchi, H., et al. (2013) · Oncogene · doi:10.1038/onc.2013.130 · Cited by 30
CyclinD1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-MB231 cells
Luo, D., Liao, D., & Sun, Y. (2012) · Journal of Carcinogenesis · doi:10.4103/1477-3163.100401 · Cited by 30
“Hyperactivation of the cyclinD1CDK4/6 exists in different types of human tumors, and targeting the CDK4/6 has been shown as a promising anticancer approach.[44,45] Unexpectedly, inhibition of CDK6[46] or CDK4[47] could restrain NF-kB signaling, and the functions conflict with the function of Gemzar.”
BackgroundRoles of NHERF Family of PDZ-Binding Proteins in Regulating GPCR Functions
Broadbent, D. G., Ahmadzai, M. M., Kammala, A. K., Yang, C., Occhiuto, C. J., Das, R., & Subramanian, H. (2017) · Advances in immunology · doi:10.1016/bs.ai.2017.05.008 · Cited by 30
Powers, S. E., Mandal, M., Matsuda, S., Miletic, A. V., Cato, M. H., Tanaka, A., Rickert, R. C., Koyasu, S., & Clark, M. R. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120800 · Cited by 33
“Although all proteins contain the N-terminal LxCxE motif (implicated in Rb binding), a cyclin box spanning the cyclin-N and cyclin-C domains and a cyclin signature CDK binding motif, the remaining sequences are divergent between family members (Musgrove et al., 2011).”
BackgroundChoi, Y. J., Sáez, B., Anders, L., Hydbring, P., Stefano, J., Bacon, N. A., Cook, C., Kalaszczyńska, I., Signoretti, S., Young, R. A., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.06.015 · Cited by 33
“These proteins are expressed in an overlapping fashion in all proliferating cell types (Musgrove et al., 2011).”
BackgroundSoleimani, Z., Kheirkhah, D., Sharif, M. R., Sharif, A., Karimian, M., & Aftabı, Y. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0165-3 · Cited by 32
“This protein composed of 5 following domains [6, 7]: 1- retinoblastoma protein (pRb) binding motif; 2- cyclin box domain; 3LxxLL binding motif; 4- PESTsequence; 5- threonine residue (threonine 286).”
BackgroundCatlin, N. R., Bowman, C., Engel, S., Sacaan, A. I., Thibault, S., Lewis, E. M., & Cappon, G. D. (2019) · Reproductive Toxicology · doi:10.1016/j.reprotox.2019.07.016 · Cited by 30
Moon, H., Jeon, S. G., Kim, J.-I., Kim, H. S., Lee, S. H., Kim, D., Park, S., Moon, M., & Chung, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010004 · Cited by 30
Zhao, M., Hu, M., Chen, Y., Liu, H., Chen, Y., Liu, B., & Fang, B. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.110 · Cited by 30
Fallah, Y., Demas, D. M., Lu, J., He, W., & Shajahan‐Haq, A. N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.681530 · Cited by 29
“Next, we assessed the protein levels cyclin D1 and phosphorRB/total RB since these are key proteins involved in signaling associated with E2 or CDK4/6 responsiveness (37, 38).”
BackgroundHou, Y., Liu, R., Xia, M., Sun, C., Zhong, B., Yu, J. Z., Ai, N., Lu, J., Ge, W., Liu, B., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105870 · Cited by 30
Targeting VPS72 inhibits ACTL6A/MYC axis activity in HCC progression
Liu, F., Liao, Z., Qin, L., Zhang, Z., Zhang, Q., Han, S., Zeng, W., Zhang, H., Liu, Y., Song, J., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000268 · Cited by 34
“[39–41] CDK4 and CCND1 play key roles in regulating the G0/G1 phase of the cell cycle, which is consistent with the conclusion that VPS72 knockdown leads to G0/G1 blockade.[42] In addition, MYC and VPS72 were independent of each other at the copy number level.”
BackgroundCDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin
Tarasewicz, E., Hamdan, R., Straehla, J. P., Hardy, A. N., Lopez, O. N., Zelivianski, S., Đokić, D., & Jeruss, J. S. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29693 · Cited by 29
“Furthermore, clinical trials implementing CDK inhibitors have indiscriminately included patients irrespective of their tumor cyclin expression profile, and, to date, one clinical trial (NCT00721409) examining the efficacy of letrozole with and without PD0332991, has specifically targeted ER breast tumors.(43) The rece…”
BackgroundResultDíaz, A., Puig‐Butillé, J. A., Valera, A., Muñoz, C., Costa, D., García‐Herrera, A., Carrera, C., Solé, F. G., Malvehy, J., Puig, S., et al. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.10.009 · Cited by 29
Wu, G., Chen, W., FAN, H., Zheng, C., Chu, J., Lin, R., Ye, J., Xu, H., Li, X., Huang, Y., et al. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1481 · Cited by 29
Ikeda, Y., Oda, K., Ishihara, H., Wada‐Hiraike, O., Miyasaka, A., Kashiyama, T., Inaba, K., Fukuda, T., Sone, K., Matsumoto, Y., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.369 · Cited by 31
“…activation of the RAS/PI3K-cyclin D1 pathway in endometrial cancer (Fukuchi et al, 1998; Moreno-Bueno et al, 2003; Oda et al, 2005, 2008; Shoji et al, 2009; Musgrove et al, 2011; Ikeda et al, 2012, 2013), which could more robustly reflect tumour aggressiveness than the expression level of Ki-67.”
BackgroundMethodInfluentialZhu, X., Zhang, Y., Li, Q., Yang, L., Zhang, N., Ma, S., Zhang, K., Song, J., & Guan, F. (2016) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21773 · Cited by 32
“the G1 phase of the cell cycle in various cell types [23].”
BackgroundPropranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib
Wei, W., Shen, C., Song, H.-J., Qiu, Z., & Luo, Q. (2016) · Oncology Reports · doi:10.3892/or.2016.4918 · Cited by 31
Velu, P., Vinothkumar, V., Babukumar, S., & Ramachandhiran, D. (2017) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2017.1349227 · Cited by 29
“Cyclin D1, a critical cell-cycle regulatory protein, drives the cell cycle from the G1 to the S phase of several studies that have shown that Cyclin D1 is amplified and overexpressed in all cancer (Fu et al. 2004; Musgrove et al. 2011).”
BackgroundInfiltrating mast cells enhance benign prostatic hyperplasia through IL-6/STAT3/Cyclin D1 signals
Ou, Z., He, Y., Qi, L., Zu, X., Wu, L., Cao, Z., Li, Y., Liu, L., Dube, D. A., Wang, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19465 · Cited by 29
“CyclinD1, a major component of cyclins, plays an important role in cell cycle progression [17].”
BackgroundLiu, J., Qian, J., Mo, Q., Tang, L., & Xu, Q. (2020) · Cancer Management and Research · doi:10.2147/cmar.s221996 · Cited by 29
Kassem, A. F., Younis, A., Nossier, E. S., Awad, H. M., & El‐Sayed, W. A. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.138741 · Cited by 28
The G 1 -S transition is promoted by Rb degradation via the E3 ligase UBR5
Zhang, S., Valenzuela, L. F., Zatulovskiy, E. A., Mangiante, L., Curtis, C. N., & Skotheim, J. M. (2024) · Science Advances · doi:10.1126/sciadv.adq6858 · Cited by 27
Elsayed, G. H., & Fahim, A. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-86096-7 · Cited by 31
Teralı, K., & Yılmazer, A. (2015) · Biochimie · doi:10.1016/j.biochi.2015.12.001 · Cited by 31
Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening
Anania, M. C., Gasparri, F., Cetti, E., Fraietta, I., Todoerti, K., Miranda, C., Mazzoni, M., Re, C. E., Colombo, R., Ukmar, G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5282 · Cited by 28
“Cyclin D1 is an important cell cycle regulator that promotes G1/S phase transition by activation of CDK4 and CDK6 kinases [26].”
Cao, W., WU, K., Wang, C., & Wan, D. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4909 · Cited by 28
“D-type cyclins, the ultimate recipients of numerous oncogenic pathways, are key signaling molecules and represent targets for cancer treatments (33).”
Liu, T., Li, W., Wang, W.-P., Sun, Y., Ni, Y., Xing, H., Xia, J., Wang, X., Zhang, Z., & Li, X. (2016) · PubMed Central · Cited by 28
Luangdilok, S., Wanchaijiraboon, P., Chantranuwatana, P., Teerapakpinyo, C., Shuangshoti, S., & Sriuranpong, V. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.12.01 · Cited by 28
“Cyclin D1 overexpression has been reported in many types of human cancers including lung cancer (8).”
BackgroundGagliato, D. D. M., Buzaid, A. C., Pérez-García, J. M., Llombart‐Cussac, A., & Cortés, J. (2020) · Cancers · doi:10.3390/cancers12092480 · Cited by 29
“In turn, the E2F transcription factor initiates a positive feedback loop, promoting transcription of the type E-cyclins, which activate CDK2 and other proteins, with further phosphorylation of RB, thus resulting in DNA synthesis [4].”
BackgroundAbdelgawad, M. A., Elkanzi, N. A. A., Nayl, A. A., Musa, A., Alotaibi, N. H., Arafa, W. A. A., Gomha, S. M., & Bakr, R. B. (2022) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2022.103781 · Cited by 32
Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
Ooki, A., Osumi, H., Chìn, K., Watanabe, M., & Yamaguchi, K. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221138377 · Cited by 31
Yadav, A. K., & Polášek-Sedláčková, H. (2024) · Communications Biology · doi:10.1038/s42003-024-05855-w · Cited by 29
Gao, G., Chen, L., Li, J., Zhang, D., Fang, Y., Huang, H., Chen, X., & Huang, C. (2014) · Oncotarget · doi:10.18632/oncotarget.1872 · Cited by 28
“Hence, cyclin D1 has been regarded as an important player in cancer development as well as a target for cancer prevention and therapy [36].”
BackgroundWang, S., Avery, J. E., Hannafon, B. N., Lind, S. E., & Ding, W. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.011 · Cited by 31
“As cyclin D1 is a downstream target of the canonical Wnt/bcatenin signaling pathway [35], and an established cancer therapeutic target [37], these results indicate that the canonical Wnt/b-catenin signaling pathway, at least in part, mediates ZnPP’s anticancer activity.”
BackgroundWang, Y., Chen, J., WANG, L., Huang, Y., Leng, Y., & Wang, G. (2013) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2013.924 · Cited by 28
“The deregulation of the cell cycle in the G1 phase has been implicated in tumor development and proliferation (35,36).”
BackgroundNovel Karyotypes and Cyclin D1 Immunoreactivity in Clear Cell Sarcoma of the Kidney
Aw, S. J., Kuick, C. H., Yong, M. H., Lian, D. W. Q., Wang, S., Loh, A. H. L., Ling, S., Peh, G. L., Soh, S. Y., Loh, A. H. P., et al. (2015) · Pediatric and Developmental Pathology · doi:10.2350/14-12-1581-oa.1 · Cited by 28
Bustany, S., Bourgeais, J., Tchakarska, G., Body, S., Hérault, O., Gouilleux, F., & Sola, B. (2016) · Oncotarget · doi:10.18632/oncotarget.9901 · Cited by 31
“Cyclin D1 is an oncogene that alters genomic stability, survival, growth and adhesion/motility [5], all which are potentially controlled by ROS production.”
BackgroundBhavani, P., Subramanian, P., & Kanimozhi, S. (2016) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-016-0605-6 · Cited by 30
Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer
Luca, A. D., Maiello, M. R., D’Alessio, A., Frezzetti, D., Gallo, M., Carotenuto, M., & Normanno, N. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1514720 · Cited by 28
“In addition, cyclin D1 enhances the activation of the estrogenreceptor α (ER α) [6].”
BackgroundPOLR1D promotes colorectal cancer progression and predicts poor prognosis of patients
Wang, M., Niu, W., Hu, R., Wang, Y., Liu, Y., Liu, L., Zhong, J., Zhang, C., You, H., Zhang, J., et al. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22966 · Cited by 27
A systematic assessment of hydroxyapatite nanoparticles used in the treatment of melanoma
Li, Z., Tang, J., Wu, H., Ling, Z., Chen, S., Zhou, Y., Guo, B., Yang, X., Zhu, X., Wang, L., et al. (2020) · Nano Research · doi:10.1007/s12274-020-2817-6 · Cited by 28
Coix Seed Oil Exerts an Anti–Triple-Negative Breast Cancer Effect by Disrupting miR-205/S1PR1 Axis
Fang, T., Jiang, Y., Chen, L., Huang, L., Tian, X.-H., Zhou, Y., Nagle, D. G., & Zhang, D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.529962 · Cited by 30
“Cyclin D1 is a tumor-associated protooncogene recognized in recent years and overexpression in various tumor cells (Musgrove et al., 2011).”
BackgroundLi, A., Wang, S., Nie, J., Xiao, S., Xie, X., Zhang, Y., Tong, W., Yao, G., Liu, N., Dan, F., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06624-7 · Cited by 33
“A Myc-tagged human USP3 expression plasmid (Myc-USP3), a Flag-tagged EPHA2 expression plasmid (Flag-EPHA2), and an HA-tagged ubiquitin (Ub) expression plasmid (HA-Ub) were generated as previously described [19, 20].”
MethodÇıtışlı, V., Dodurga, Y., Güneş, C. E., Seçme, M., Avcı, Ç. B., & Şatıroğlu-Tufan, N. L. (2015) · Tumor Biology · doi:10.1007/s13277-015-3373-7 · Cited by 27
“Previous studies exhibited that overexpression or amplification of Cyclin D1 promotes tumor growth in many different cancer types [34, 35].”
BackgroundTang, J. Y., Liao, Y., He, S., Shi, J., Peng, L., Xu, X., Xie, F., Diao, N., Huang, J., Xie, Q. R., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1342-1 · Cited by 28
“Cyclin D1 is frequently deregulated in cancer and is a biomarker of cancer phenotypes and disease progression [29].”
BackgroundVisweswaran, M., Arfuso, F., Dilley, R. J., Newsholme, P., & Dharmarajan, A. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.12.013 · Cited by 27
Bouclier, C., Simon, M., Laconde, G., Pellerano, M., Diot, S., Lantuéjoul, S., Busser, B., Vanwonterghem, L., Vollaire, J., Josserand, V., et al. (2020) · Theranostics · doi:10.7150/thno.40971 · Cited by 27
“In agreement with other studies [5, 7], we found high levels of cyclin D1 and CDK4 in invasive NSCLC samples.”
BackgroundResultMokgautsi, N., Wang, Y., Lawal, B., Khedkar, H., Sumitra, M. R., Wu, A. T. H., & Huang, H. (2021) · Cancers · doi:10.3390/cancers13112523 · Cited by 27
“Recent studies have demonstrated that cyclin D1 (CCND1) plays a significant role in regulating the cell cycle, thereby promoting tumor proliferation, invasion, and metastasis [7], as well as angiogenesis and resistance to chemotherapy and radiotherapy in multiple cancer types [8,9].”
BackgroundZhu, D., Huang, J., Liu, N., Li, W., & Yan, L. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03981-5 · Cited by 30
Huang, J., Wang, X., Dong, R., Liu, X., Li, H., Zhang, T., Xu, J., Liu, C., Zhang, Y., Hou, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00271 · Cited by 28
Romero, S. A., Pavan, I. C. B., Morelli, A. P., Mancini, M. C. S., da Silva, L. G. S., Fagundes, I., Silva, C. H. R., Ponte, L. G. S., Rostagno, M. A., Bezerra, R. M. N., et al. (2021) · Phytotherapy Research · doi:10.1002/ptr.7255 · Cited by 29
Lin, J., Fang, S.-U., Su, C.-L., Hsiao, C.-J., Chang, C., Lin, Y., & Cheng, C. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.10.006 · Cited by 27
“The eukaryotic cell cycle is regulated by the synthesis of individual cyclins and their catalytic CDK activation at specific cell-cycle stages, to coordinate the sequential completion of DNA replication and cell division [22,33].”
BackgroundInfluentialZhang, X., Lee, S., Min, K., McEntee, M. F., Jeong, J. B., Li, Q., & Baek, S. J. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0220 · Cited by 27
“The activated cyclin D1-CDK4/6 complex phosphorylates Rb protein and subsequently induces the expression of E2F-target genes that are necessary for DNA synthesis (15).”
BackgroundPark, S. B., Park, G. H., Song, H. M., Son, H.-J., Um, Y., Kim, H., & Jeong, J. B. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-1954-2 · Cited by 28
“5% and 55% in human colorectal cancer, respectively [35].”
BackgroundKaiso is highly expressed in TNBC tissues of women of African ancestry compared to Caucasian women
Bassey-Archibong, B. I., Hercules, S. M., Rayner, L. G. A., Skeete, D. H.-A., Connell, S. P. S., Brain, I., Daramola, A. O., Banjo, A. A. F., Byun, J. S., Gardner, K. L., et al. (2017) · Cancer Causes & Control · doi:10.1007/s10552-017-0955-2 · Cited by 31
Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer
Berry, W., Lundy, J., Croagh, D. G., & Jenkins, B. J. (2018) · Cancers · doi:10.3390/cancers10020035 · Cited by 27
TELANG, N. T., Nair, H. B. B., & Wong, G. (2019) · Oncology Letters · doi:10.3892/ol.2019.10182 · Cited by 28
Chinnapaka, S., Zheng, G., Chen, A., & Munirathinam, G. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.08.025 · Cited by 27
“However, NCX4040 down regulates the expression of cell cycle specific CyclinD1 expression which plays an important role in oncogenic transformation and over expressed in cancer cells [60].”
BackgroundTanaka, Y., Momose, S., Tabayashi, T., Sawada, K., Yamashita, T., Higashi, M., Sagawa, M., Tokuhira, M., Rosenwald, A., Kizaki, M., et al. (2019) · Cancer Science · doi:10.1111/cas.14286 · Cited by 30
Gambogenic acid exerts anticancer effects in cisplatin‑resistant non‑small cell lung cancer cells
Shen, D.-F., Wang, Y., Niu, H., & Liu, C. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.10909 · Cited by 30
Tilley, F. C., Arrondel, C., Chhuon, C., Boisson, M., Cagnard, N., Parisot, M., Menara, G., Lefort, N., Guerrera, I. C., Bôle‐Feysot, C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84472-7 · Cited by 27
Huang, Y., Yang, M., Hu, H., Zhao, X., Bao, L., Huang, D., Song, L., & Li, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9167 · Cited by 27
“Aberrant STAT3 occurs in most GCs and contributes to oncogenesis and aggressive GC biology by the upregulation of critical genes [6-8, 12-14] and the dysregulation of cell growth and survival [1-2, 5-8, 13-14].”
BackgroundLian, S., Park, J. G., Xia, Y., Nguyen, T. P., Joo, Y., Kim, K. K., Kim, H. K., & Jung, Y. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101633 · Cited by 26
“Cyclin-D forms a complex with and functions as a regulatory subunit of CDK, which is required for the cell cycle G1/S transition [40].”
BackgroundA Network Analysis of Multiple Myeloma Related Gene Signatures
Liu, Y., Yu, H., Yoo, S., Lee, E., Laganà, A., Parekh, S. S., Schadt, E. E., Wang, L., & Zhu, J. (2019) · Cancers · doi:10.3390/cancers11101452 · Cited by 26
“genes, CCND1-3, highly expressed, and the CD4/6-Rb pathway [63] activated.”
BackgroundYan, F., Ma, Y., Liu, L., Li, L., Deng, J., & Sun, J. (2020) · Journal of Surgical Research · doi:10.1016/j.jss.2020.05.078 · Cited by 26
Pysz, M. A., Hao, F., Hizli, A. A., Lum, M. A., Swetzig, W. M., Black, A. R., & Black, J. D. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.571554 · Cited by 28
“Although the Sp1 mutation also introduces a mutation into the Egr1b site, this site is expected to retain the ability to bind Egr1 (28).”
BackgroundInfluentialAntosova, B., Smolikova, J., Borkovcova, R., Strnad, H., Láchová, J., Machoň, O., & Kozmík, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078279 · Cited by 26
“Cyclin D1 and cyclin D2 are closely related G1 cyclins [54].”
BackgroundDamnacanthal and its nanoformulation exhibit anti-cancer activity via cyclin D1 down-regulation
Sukamporn, P., Rojanapanthu, P., SILVA, G. H. D. O., Zhang, X., Gritsanapan, W., & Baek, S. J. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.03.038 · Cited by 26
Clostridium difficile Toxin A Attenuates Wnt/β-Catenin Signaling in Intestinal Epithelial Cells
Lima, B. B., Fonseca, B. F., Amado, N. G., Lima, D. M., Ribeiro, R. A., Abreu, J. G., & Brito, G. A. D. C. (2014) · Infection and Immunity · doi:10.1128/iai.00567-13 · Cited by 26
Gambogic Acid and Its Role in Chronic Diseases
Pandey, M. K., Karelia, D. N., & Amin, S. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-41334-1_15 · Cited by 27
Litchfield, L. M., Boehnke, K., Brahmachary, M., Mur, C., Chen, B., Stephens, J. R., Sauder, J. M., Gutiérrez, S. M., McNulty, A. M., Ye, X. S., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27539 · Cited by 32
Raimondi, L., Raimondi, F. M., Pietranera, M., Rocco, A. D., Benedetto, L. D., Miele, E., Lazzeroni, R., Cimino, G. G., & Spinelli, G. P. (2021) · Cancers · doi:10.3390/cancers13081928 · Cited by 26
“(in 2019) showed that a downstream effector of KRAS is Cyclin D1/CCND1, which seems to control cell division by regulating CDK4/6 activity during the G1-S transition of the cell cycle [14,15].”
BackgroundSong, B.-N., Kim, S., & Chu, I. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.120 · Cited by 26
Hong, H., An, J. C., Cruz, J. F. D., & Hwang, S.-G. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4916 · Cited by 25
“Interestingly, Musgrove et al claimed that cyclin D is one of the therapeutic target molecules in cancer therapy (28).”
High LINC00536 expression promotes tumor progression and poor prognosis in bladder cancer
Li, R., Zhang, L., Qin, Z., Wei, Y., Deng, Z., Zhu, C. Y., Tang, J., & Ma, L. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.03.009 · Cited by 25
Liss, F., Frech, M., Wang, Y., Giel, G., Fischer, S., Simon, C., Weber, L. M., Nist, A., Stiewe, T., Neubauer, A., et al. (2021) · Cancers · doi:10.3390/cancers13040764 · Cited by 25
“Cyclin D1 is often upregulated in cancer and a master regulator of G1 phase progression [61].”
BackgroundPaul, E. N., Burns, G. W., Carpenter, T. J., Grey, J. A., Fazleabas, A. T., & Teixeira, J. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073618 · Cited by 25
“Genes of interest involved in tumor progression or uterine fibroids, from previous studies, FGFR1 [18], CCND1 [19], PCDH11X [20], VDR [21], NDRG2 [22] and INPP4B [23], are indicated in the volcano plot.”
BackgroundObata, T., Tsutsumi, K., Ueta, E., Oda, T., Kikuchi, T., Ako, S., Fujii, Y., Yamazaki, T., Uchida, D., Matsumoto, K., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102054 · Cited by 26
“Moreover, miR-451a may inhibit the AKT/Cyclin D1 signaling pathway 41 – 43 and other MIF-mediated pathways.”
BackgroundSTOP gene Phactr4 is a tumor suppressor
Solimini, N. L., Liang, A. C. T., Xu, C., Pavlova, N. N., Xu, Q., Davoli, T., Li, M. Z., Wong, K., & Elledge, S. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221385110 · Cited by 25
“Forced cyclin D overexpression in transgenic animals also drives tumorigenesis, and its overproduction is a common feature of human cancers (9).”
BackgroundAndrogen receptor co-regulatory networks in castration-resistant prostate cancer
Sung, Y. Y., & Cheung, E. C. W. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0326 · Cited by 26
“Despite being frequently over-expressed in many tumor types, cyclin D1a is rarely deregulated in prostate cancer and has not been reported to have any independent prognostic value in this type of cancer (Han et al. 1998, Aaltomaa et al. 1999, Musgrove et al. 2011).”
BackgroundLuciani-Torres, M. G., Moore, D. H., Goodson, W. H., & Dairkee, S. H. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu234 · Cited by 29
“It is not surprising therefore that overexpression of p21 is common in many human cancers, and generally correlated with poor prognosis (34,35).”
BackgroundA mathematical model of subpopulation kinetics for the deconvolution of leukaemia heterogeneity
Fuentes‐Garí, M., Misener, R., Munzer, D. G., Velliou, E. G., Georgiadis, M. C., Kostoglou, M., Pistikopoulos, E. N., Panoskaltsis, N., & Mantalaris, A. (2015) · Journal of The Royal Society Interface · doi:10.1098/rsif.2015.0276 · Cited by 26
SRSF3-regulated miR-132/212 controls cell migration and invasion by targeting YAP1
Kim, H. R., Hwang, S. J., Shin, C. H., Choi, K. H., Ohn, T., & Kim, H. H. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.06.009 · Cited by 27
“Moreover, it is a biomarker of cancer phenotypes and disease progression [25,26].”
Chao, S.-W., Chen, L., Yu, C.-C., Liu, C., Lin, T. E., Guh, J., Wang, C.-Y., Chen, C.-Y., Hsu, K., & Huang, W. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.092 · Cited by 25
Zhao, C., Li, Y., Zhang, W., Zhao, D., Ma, L., Ma, P., Yang, F., Wang, Y., Shu, Y., & Qiu, W. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4307 · Cited by 25
“Reportedly, cyclin D1 is widely overexpressed in certain types of human cancer, and several growth factors, such as epidermal growth factor ( EGF ) markedly enhance cancer cell proliferation by increasing cyclin D1 expression (25,26).”
Chen, Y., Chang, I. Y., Liu, H., Ma, C., Kuo, Y., Shih, C., Shih, Y.-H., Kang, L., & Tan, B. C. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001197 · Cited by 26
“We then selected one of the targets, CCND1, for further characterization because of its close link to cancer cell growth and survival (33).”
McCann, J. L., Klein, M. M., Leland, E. M., Law, E. K., Brown, W. L., Salamango, D. J., & Harris, R. S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008443 · Cited by 27
Yan, G., Dai, M., Zhang, C., Poulet, S., Moamer, A., Wang, N., Boudreault, J., Ali, S., & Lebrun, J. J. (2021) · Oncogenesis · doi:10.1038/s41389-021-00310-5 · Cited by 27
Modeling Prolactin Actions in Breast Cancer In Vivo: Insights from the NRL-PRL Mouse
O’Leary, K. A., Shea, M. P., & Schuler, L. A. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-12114-7_9 · Cited by 25
“The cell cycle regulator, cyclin D1, is the major D cyclin in the mammary gland and is overexpressed in many breast cancers (for review, [62]).”
BackgroundBhaskaran, S., Dileep, K. V., Deepa, S. S., Sadasivan, C., Klausner, M., Krishnegowda, N. K., TEKMAL, R. R., VandeBerg, J. L., & Nair, H. B. B. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0965 · Cited by 25
“Under normal conditions, CDK4 forms a complex with cyclin D1 leading to the activation of E2F target genes, including cyclin D1, through phosphorylation of Rb (49).”
BackgroundDu, M., Yu, Q., Lu, F., Luo, M., Shao, S. H., Huang, S., Wang, G., Jing, X., Tong, Z., Zhao, X., et al. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02003-9 · Cited by 25
Metadata
- Authors
- Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L.
- Affiliations
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Sutherland, Robert L.
- ORCID
- Caldon, C. Elizabeth
- Venue
- Nature Reviews Cancer
- Published
- 2011-07-07
- Volume
- 11
- Issue
- 8
- Pages
- 558-572
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2089655089
- Cited by
- 1,370
- References
- 190
- Citations by year
- 2026: 54 · 2025: 65 · 2024: 57 · 2023: 78 · 2022: 85 · 2021: 102 · 2020: 113 · 2019: 100 · 2018: 93 · 2017: 130 · 2016: 129 · 2015: 105 · 2014: 92 · 2013: 91 · 2012: 75
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- cyclin D1, cyclin D, cyclin-dependent kinases, CDK4, CDK6, oncogene deregulation, cancer therapy, therapeutic target, biomarkers, patient subgroup identification, tumor progression
- MeSH terms
- Humans, Neoplasms, Oncogenes, Polymorphism, Genetic, Cyclin D
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.